Arax Advisory Partners’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
Arax Advisory Partners's SYRE Position: Q3 2026 in Review
Arax Advisory Partners increased its Spyre Therapeutics (SYRE) stake by 8.3% in Q3 2026, buying an estimated $1.35K and bringing the position to 183 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4147.
Arax Advisory Partners first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. 193 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- Arax Advisory Partners held 183 shares of Spyre Therapeutics worth $16.3K as of Q3 2026.
- Arax Advisory Partners bought 14 Spyre Therapeutics shares in Q3 2026, an estimated $1.35K.
- Spyre Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4147 holding.
- Arax Advisory Partners first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
- 193 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.